$DORM

Dorman Products (DORM) Q2 2026 Earnings Call Transcript

Dorman Products (DORM) reported Q2 2026 net sales of $544.6 million (+0.7%) and adjusted diluted EPS of $3.08 (+50%), helped by a $1.18 per share IEEPA tariff refund. Adjusted gross margin rose to 46.1%. FY2026 guidance: net sales growth 3% to 5% and adjusted EPS $8.50 to $8.80.

Original reporting
Published Aug 11, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 4:08 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dorman Products (DORM) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$DORMBullishMed
01

Why it matters

The key tradable items are the guidance revisions (net sales down, adjusted EPS up), the explicit per-share IEEPA refund impact, and the stated normalized gross margin target for year-end 2026 that informs 2027 earnings power.

02

Market read

Traders can reprice DORM based on the tension between refund-driven EPS upside and lowered revenue guidance, plus management’s normalization targets for gross margin.

03

What to watch

Management flags potential SG&A deleverage in the back half due to lower projected revenue growth, which could offset margin gains if operating leverage does not materialize.

Relevance 8/10Novelty 8/10Timing: ahead of the market’s next earnings/guidance positioning for FY 2026

Background

This is Dorman Products’ Q2 2026 earnings call transcript, centered on tariff stabilization and IEEPA refund recovery affecting reported versus comparable margins.

Company-level read

Ticker impact

$DORMBullishMedium confidence
Context

Dorman reported Q2 results and raised FY 2026 adjusted EPS guidance to $8.50 to $8.80, citing IEEPA tariff refund recovery.

Expected impact

Near-term trading likely hinges on how investors discount the IEEPA refund versus the lowered net sales guidance and any implied margin normalization.

Evidence & confidence

The call provides explicit EPS and net sales guidance changes plus margin normalization targets, which can drive re-rating if the market focuses on normalized earnings power rather than refund-driven optics.

Market effects

Tariff pass-through and refund timing are highlighted as key margin drivers for auto aftermarket suppliers, potentially affecting how peers model gross margin normalization.

No specific regional demand shock is disclosed beyond general freight recession and consumer sentiment commentary.

International expansion is mentioned for Super ATV, but no quantified global demand or tariff exposure changes are provided.

Counterpoint

Investors may treat the raised EPS range as less durable because comparable margins excluding refunds remain materially lower, and net sales guidance was reduced.

Key entities

  • Dorman Products, Inc.

    Auto parts supplier reporting Q2 2026 results, IEEPA refund impact, and revised FY 2026 guidance.

  • Kevin Olsen

    CEO who discussed tariff pass-through philosophy and segment headwinds.

  • Charles Rayfield

    CFO who discussed comparable EPS and guidance framing excluding the one-time refund benefit.

Related articles

$DORMMedAI 8/10

Dorman Products Q2 net sales rise to $544.6 million

Dorman Products reported Q2 2026 net sales of $544.6 million, up 0.7% from $541.0 million. Net income rose to $87.8 million and diluted EPS increased 53% to $2.93, aided by IEEPA tariff cost recovery, according to the company. Operating cash flow was $152.6 million; it repurchased $47 million of shares. Updated guidance: net sales growth 3% to 5% and EPS $7.93 to $8.23.

$DORMMed

Dorman Products, Inc. (DORM): Results of Operations and Financial Condition

Dorman Products, Inc. (DORM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dorm-20260627xexx991.htm EX-99.1 Document Exhibit 99.1 Dorman Products, Inc. Reports Second Quarter 2026 Results; Updates 2026 Guidance Highlights (All comparisons are to the prior year period unless otherwise noted) : • Net sales of $544.6 million for the quarter, up 0

$HALOHighAI 9/10

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

Halozyme Therapeutics (NASDAQ:HALO) shares rose about 18% after the company reported Q2 adjusted EPS of $2.28 on revenue of $481 million, beating consensus of $1.82 and $404.3 million. Halozyme cited 47.7% YoY revenue growth from ENHANZE royalties and milestones. It raised full-year guidance to $1.87B revenue and $8.83 adjusted EPS midpoint.

$FIVNHighAI 9/10

Five9 (FIVN) Stock Trades Up, Here Is Why

Five9 (NASDAQ:FIVN) shares rose about 18% after the company reported Q2 results above Wall Street expectations. Adjusted EPS was $0.70 on revenue of $312.4 million, with revenue up 10.3% year over year. Five9 raised full-year revenue guidance to $1.27 billion at the midpoint and forecast next-quarter sales above consensus.

$SMCIHigh

Super Micro Already Told Us Its Revenue, Its Margins, and Its Orders. Tuesday's Report Has One Number Left.

Super Micro Computer (SMCI) preannounced fiscal Q4 results for the period ended June 30, saying revenue would be near the low end of $11.0B to $12.5B, gross margin 15% to 17%, and new orders over $60B, lifting backlog to record levels. The full results on Tuesday are expected to include a fiscal 2027 outlook. Shares trade in the low $30s, down about 45% from the 52-week high.

$PLBYMed

Honey Birdette’s comp sales jump 15%

Playboy Inc. said its Honey Birdette brand delivered 18.2% year-over-year sales growth in Q2 2026, with gross margin at 65.1%. Comparable store sales rose 15%. Playboy reported group sales up 11% to US$31.2m, DTC revenue at US$19.5m, and net income of US$0.2m versus a US$7.7m loss a year earlier.